Publications Search

Search for publications by author
Search for publications by abstract keyword(s)

Inhibition of sclerostin systemic treatment with sclerostin antibody enhances healing of proximal tibial defects in ovariectomized rats.


Recent studies suggest a possible role for inhibitors of sclerostin such as sclerostin antibody (Scl-Ab) as an anabolic treatment for osteoporosis. Since Scl-Ab has also been shown to potentiate bone repair, we examined the effect of Scl-Ab treatment in a metaphyseal defect repair model in ovariectomized (OVX) rats. Four weeks after OVX or sham surgery, 3 mm circular defects were created bilaterally in the proximal tibia of all rats. After defect surgery, Saline or 25 mg/kg Scl-Ab was administered twice weekly for 3 weeks. Of note, healing was advanced in the 1-week post-defect surgery in OVX controls over Sham controls, with increases in bone volume and fluorochrome labeling observed. However, by week 2, OVX controls fell significantly behind in the repair response compared with Sham controls. Scl-Ab treatment significantly increased bone volume in the defect in OVX rats over the 3-week time course as examined by either microCT or histology. Significant increases in bone formation via fluorochrome labeling of the new bone were observed with Scl-Ab treatment, while osteoclast parameters were not different. With its powerful anabolic potential, bone-specific activity, and potential for low dosing frequency, Scl-Ab treatment could provide enhanced bone repair, particularly in situations of compromised bone repair such as osteoporotic bone.

Type Journal
Authors McDonald, M.M.; Morse, A.; Mikulec, K.; Peacock, L.; Yu, N.; Baldock, P.A.; Birke, O.; Liu, M.; Ke, H.Z.; Little, D.G.
Responsible Garvan Author Dr Michelle McDonald
Published Date 2012-03-30
Published Volume 30
Published Issue 10
Published Pages 1541-8
Status Published in-print
DOI 10.1002/jor.22109
URL link to publisher's version
OpenAccess link to author's accepted manuscript version